Now Enrolling: A Clinical Study for Adult Patients with Polycythaemia Vera (PV)
SANRECO is a global phase 2 clinical study evaluating SLN124, an investigational treatment for adults living with PV.
Healthcare professionals with potentially eligible patients, as well as patients, caregivers, and advocates, are encouraged to learn more and see if participation may be an option.
Now Enrolling: A Clinical Study for Adult Patients with Polycythaemia Vera (PV)
SANRECO is a global phase 2 clinical study evaluating SLN124, an investigational treatment for adults living with PV.
Healthcare professionals with potentially eligible patients, as well as patients, caregivers, and advocates, are encouraged to learn more and see if participation may be an option.
What Is SLN124 And How Does It Work?
- SLN124 is an investigational gene silencing therapy, or siRNA (short interfering RNA), in development as a potential treatment for PV.
- SLN124 works by temporarily silencing the production of the TMPRSS6 protein found in liver cells, which in turn increases the body’s production of another protein called hepcidin. By increasing hepcidin levels, SLN124 aims to redirect iron delivery away from the bone marrow, lowering red blood cell production and potentially reducing the high red blood cell count in people living with PV. This may reduce the need for phlebotomies and lower the risk of blood clots and strokes. In addition, PV related symptoms such as fatigue, brain fog, and itchy skin may be reduced.
Our Commitment To Answering Patient Needs
Silence Therapeutics, the study sponsor, is a global clinical-stage biotechnology company and pioneer in siRNA therapeutics. We are committed to developing innovative medicines with the potential to transform the lives of people affected by rare and common diseases with unmet needs, including PV.
